Hope and fear for new classes of type 2 diabetes drugs: Is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages

  Lamont, Benjamin J ^a   Andrikopoulos, Sofianos ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cells; DPP4; GLP1; Islets; Mice; Pancreatitis; Rats

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; BROXURIDINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; KI 67 ANTIGEN; LIRAGLUTIDE; SITAGLIPTIN; VILDAGLIPTIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; EXPERIMENTAL PANCREATITIS; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GOTO KAKIZAKI RAT; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PANCREATITIS; PRIORITY JOURNAL; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; WEIGHT REDUCTION; ZUCKER DIABETIC FATTY RAT;

DPP4; GLP1; ISLETS; MICE; PANCREATITIS; RATS; Β-CELLS;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREAS;

EID: 84897823030     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0577     Document Type: Article

References (97)

1. Ahmad SR & Swann J 2008 Exenatide and rare adverse events. New England Journal of Medicine 358 1971-1972 (discussion 1971-1972)
2. Aho HJ, Koskensalo SM & Nevalainen TJ 1980 Experimental pancreatitis in the rat. Sodium taurocholate-induced acute haemorrhagic pancreatitis Scandinavian Journal of Gastroenterology 15 411-416
3. Aston-Mourney K, Proietto J, Morahan G & Andrikopoulos S 2008 Toomuch of a good thing: why it is bad to stimulate the b cell to secrete insulin Diabetologia 51 540-545
4. Aston-Mourney K, Subramanian SL, Zraika S, Samarasekera T, Meier DT, Goldstein LC & Hull RL 2013 One year of sitagliptin treatment protects against islet amyloid-associated β-cells loss and does not induce pancreatitis or pancreatic neoplasia in mice. American Journal of Physiology. Endocrinology and Metabolism 305 E475-E484
5. Baggio LL, Huang Q, Cao X & Drucker DJ 2008 An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134 1137-1147
6. Bock T, Pakkenberg B & Buschard K 2003 The endocrine pancreas in nondiabetic rats after short-term and long-term treatment with the longacting GLP-1 derivative NN2211. APMIS 111 1117-1124
7. Bonner-Weir S, Trent DF & Weir GC 1983 Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. Journal of Clinical Investigation 71 1544-1553
8. Bonner-Weir S, In't Veld P & Weir G 2014 Re-analysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes, Obesity & Metabolism [in press]
9. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H & DiamantM 2011 Effects of exenatide on measures of β-cells function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 2041-2047
10. Busch SJ, Hoffmann P, Sahota P, Johnson R, KothnyW, Meyer F & Foley JE 2013 Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes, Obesity & Metabolism 15 72-76
11. Buteau J, Spatz ML & Accili D 2006 Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cells mass. Diabetes 55 1190-1196
12. Butler AE, Jang J, Gurlo T, Carty MD, SoellerWC & Butler PC 2004 Diabetes due to a progressive defect in β-cells mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes Diabetes 53 1509-1516
13. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M & Butler PC 2013 Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62 2595-2604
14. Chadwick KD, Fletcher AM, ParrulaMC, Bonner-Weir S,Mangipudy RS, Janovitz E, Graziano MJ, Roy D & Reilly TP 2013 Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor inthenonclinical assessmentofglucagon-likepeptide (GLP)-1-based therapies. Diabetes [in press]
15. Coleman DL 1978 Obese and diabetes: two mutant genes causing diabetes- obesity syndromes in mice. Diabetologia 14 141-148
16. Costes S, Huang CJ, Gurlo T, Daval M,Matveyenko AV, Rizza RA, Butler AE & Butler PC 2011 β-cells dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptideinduced UCH-L1 deficiency. Diabetes 60 227-238
17. Drucker DJ 2011 Incretin-based therapy and the quest for sustained improvements in β-cells health. Diabetes Care 34 2133-2135
18. Drucker DJ 2013 Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62 3316-3323
19. Duez H, Smith AC, Xiao C, Giacca A, Szeto L, Drucker DJ & Lewis GF 2009 Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulinmediated suppression of endogenous glucose production in mice Endocrinology 150 56-62
20. Duttaroy A,Voelker F,MerriamK,ZhangX,RenX, SubramanianK,HughesTE & Burkey BF 2011 The DPP-4 inhibitor vildagliptin increases pancreatic b cell mass in neonatal rats. European Journal of Pharmacology 650 703-707
21. Elashoff M, Matveyenko AV, Gier B, Elashoff R & Butler PC 2011 Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141 150-156
22. Ellenbroek JH, Tons HA, Westerouen van Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F & de Koning EJ 2013 Glucagonlike peptide-1 receptor agonist treatment reduces b cell mass in normoglycaemic mice. Diabetologia 56 1980-1986
23. Engel SS, Golm GT & Lauring B 2013 Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604. Diabetes 62 e18
24. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U & Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 4397-4408
25. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T & Buckingham RE 2001 β-cells mass dynamics in Zucker diabetic fatty rats, Rosiglitazone prevents the rise in net cell death. Diabetes 50 1021-1029
26. Gale EA 2013 GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ 346 f1263.
27. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B & Group L-S 2011 Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 13 348-356
28. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG & Young AA 2005 Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146 2069-2076.
29. Gier B & Butler PC 2013 Glucagon-like peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer? JAMA Internal Medicine 173 539-541
30. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM & Butler PC 2012 Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61 1250-1262
31. Girman CJ, Kou TD,Cai B, AlexanderCM, O'Neill EA, Williams-HermanDE& KatzL2010Patientswithtype2 diabetesmellitushavehigher risk for acute pancreatitis compared with those without diabetes. Diabetes, Obesity & Metabolism 12 766-771
32. Han SJ, Choi SE, Kang Y, Jung JG, Yi SA, Kim HJ, Lee KW & Kim DJ 2011 Effect of sitagliptin plus metformin on β-cells function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Research and Clinical Practice 92 213-222
33. Harja E, Lord J & Skyler JS 2013 An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technology & Therapeutics 15 609-618
34. Heine RJ, Fu H, Kendall DM & Moller DE 2013 Comment on: Butler et al Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors Diabetes 2013;62:2595-2604. Diabetes 62 e16-e17
35. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA & Butler PC 2007 High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated β-cells apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56 2016-2027
36. Hui H, Nourparvar A, Zhao X & Perfetti R 2003 Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 50-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 1444-1455
37. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL & Kahn SE 2003 Increased dietary fat promotes islet amyloid formation and β-cells secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52 372-379
38. Hull RL, Zraika S, Udayasankar J, Aston-Mourney K, Subramanian SL & Kahn SE 2009 Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 52 1102-1111
39. Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K & Yagihashi S 2012 Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. European Journal of Pharmacology 691 297-306
40. Kahn SE 2013 Incretin therapy and islet pathology: a time for caution Diabetes 62 2178-2180
41. KimJG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C & Drucker DJ 2003 Development and characterization of a glucagonlike peptide 1-albumin conjugate: the ability to activate the glucagonlike peptide 1 receptor in vivo. Diabetes 52 751-759
42. Koehler JA, Baggio LL, Lamont BJ, Ali S & Drucker DJ 2009 Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58 2148-2161
43. Kwon DY, Kim YS, Ahn IS, Kim da S, Kang S, Hong SM & Park S 2009 Exendin-4 potentiates insulinotropic action partly via increasing β-cells proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. Journal of Pharmacological Sciences 111 361-371
44. Lamont BJ & Drucker DJ 2008 Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57 190-198
45. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H & Drucker DJ 2012 Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. Journal of Clinical Investigation 122 388-402
46. Lerch MM & Gorelick FS 2013 Models of acute and chronic pancreatitis Gastroenterology 144 1180-1193
47. Li Y, Hansotia T, Yusta B, Ris F, Halban PA & Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates b cell apoptosis. Journal of Biological Chemistry 278 471-478
48. Li Y, Cao X, Li LX, Brubaker PL, Edlund H & Drucker DJ 2005 β-cells Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 482-491
49. Lovshin JA & Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews. Endocrinology 5 262-269
50. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T & Donath MY 2005 Sulfonylurea induced β-cells apoptosis in cultured human islets Journal of Clinical Endocrinology and Metabolism 90 501-506
51. Maida A, Hansotia T, Longuet C, Seino Y & Drucker DJ 2009 Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for b cell survival in mice Gastroenterology 137 2146-2157
52. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR & Gagliardino JJ 2011 Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cells apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clinical Science 120 73-80
53. Matveyenko AV & Butler PC 2006 β-cells deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 55 2106-2114
54. Matveyenko AV, Dry S, CoxHI, Moshtaghian A,Gurlo T, Galasso R, Butler AE & Butler PC 2009 Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58 1604-1615
55. Movassat J, Saulnier C & Portha B 1995 β-cells mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulindependent diabetes mellitus. Diabetes & Metabolism 21 365-370
56. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD et al. 2006 Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cells mass and function in a rodent model of type 2 diabetes. Diabetes 55 1695-1704
57. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS et al. 2009 Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European Journal of Pharmacology 623 148-154
58. Nachnani JS, Bulchandani DG, Nookala A, Herndon B,Molteni A, Pandya P, Taylor R, Quinn T, Weide L & Alba LM 2010 Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas Diabetologia 53 153-159
59. Nauck MA 2013 A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36 2126-2132
60. Noel RA, Braun DK, Patterson RE & Bloomgren GL 2009 Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32 834-838
61. Nyborg NC, Molck AM, Madsen LW & Knudsen LB 2012 The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 61 1243-1249
62. Omar BA, Vikman J, Winzell MS, Voss U, Ekblad E, Foley JE & Ahren B 2013 Enhanced β cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 56 1752-1760
63. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G & White MF 2006 Exendin-4 uses Irs2 signaling to mediate pancreatic b cell growth and function. Journal of Biological Chemistry 281 1159-1168
64. Parkes DG, Mace KF & Trautmann ME 2013 Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opinion on Drug Discovery 8 219-244
65. Perfetti R, Zhou J, Doyle ME & Egan JM 2000 Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141 4600-4605
66. Rankin MM & Kushner JA 2009 Adaptive β-cells proliferation is severely restricted with advanced age. Diabetes 58 1365-1372
67. Rankin MM, King KB, Kim JJ, Li C & Kushner JA 2012 New b cells are not generated by prolonged administration of incretin-based therapies (Exendin-4 or Sitagliptin) in adult mouse pancreas. Diabetes 61(suppl 1A) LB34
68. Raschi E, Piccinni C, Poluzzi E, Marchesini G & De Ponti F 2013 The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica 50 569-577
69. Reimer MK, Holst JJ & Ahren B 2002 Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. European Journal of Endocrinology 146 717-727
70. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M & Knudsen LB 2002 The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cells mass in diabetic mice American Journal of Physiology. Endocrinology and Metabolism 283 E745-E752
71. Sato K, Nakamura A, Shirakawa J,Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T & Terauchi Y 2012 Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cells function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology 153 1093-1102
72. Shimizu S, Hosooka T, Matsuda T, Asahara S, Koyanagi-KimuraM, Kanno A, Bartolome A, Etoh H, Fuchita M, Teruyama K et al. 2012 DPP4 inhibitor vildagliptin preserves β-cells mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice Journal of Molecular Endocrinology 49 125-135
73. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E et al. 2011a Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased b cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. Journal of Biological Chemistry 286 25467-25476
74. Shirakawa J, Fujii H,OhnumaK, Sato K, Ito Y, KajiM, Sakamoto E, Koganei M, Sasaki H, Nagashima Y et al. 2011b Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60 1246-1257
75. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM & Segal JB 2013 Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Internal Medicine 173 534-539
76. Stamateris RE, Sharma RB, Hollern DA & Alonso LC 2013 Adaptive β-cells proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression American Journal of Physiology. Endocrinology and Metabolism 305 E149-E159
77. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF & Egan JM 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 741-748
78. Stoffers DA, Desai BM, DeLeon DD & Simmons RA 2003 Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52 734-740
79. Strobel O, Rosow DE, Rakhlin EY, Lauwers GY, Trainor AG, Alsina J, Fernandez-Del Castillo C, Warshaw AL & Thayer SP 2010 Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 138 1166-1177
80. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD et al. 2003 GLP-1 derivative liraglutide in rats with β-cells deficiencies: influence of metabolic state on β-cells mass dynamics. British Journal of Pharmacology 140 123-132
81. Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, IkedaH, Yamada Y, Inagaki N & Seino Y 2007 Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic β-cells death in the chronic phase. Diabetes Research and Clinical Practice 77 343-350
82. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, Makino Y, Abiko A, Kieffer TJ& Haneda M 2012 Reduction of both b cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice Diabetologia 55 404-412
83. Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L et al. 2010 Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. American Journal of Physiology Endocrinology and Metabolism 299 E1076-E1086
84. Tatarkiewicz K, Belanger P,GuG, Parkes D&Roy D 2013Noevidence of druginduced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes, Obesity & Metabolism 15 417-426
85. Tourrel C, Bailbe D, Meile MJ, Kergoat M & Portha B 2001 Glucagon-like peptide-1 and exendin-4 stimulate β-cells neogenesis in streptozotocintreated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 1562-1570
86. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M & Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cells mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 1443-1452
87. Trumper A, Trumper K & Horsch D 2002 Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in b(INS-1)-cells. Journal of Endocrinology 174 233-46
88. Tschen SI, Dhawan S, Gurlo T & Bhushan A 2009 Age-dependent decline in β-cells proliferation restricts the capacity of β-cells regeneration in mice Diabetes 58 1312-1320
89. Ussher JR & Drucker DJ 2012 Cardiovascular biology of the incretin system Endocrine Reviews 33 187-215
90. Verchere CB, D'Alessio DA, Palmiter RD, WeirGC, Bonner-Weir S, BaskinDG & Kahn SE 1996 Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic b cell expression of human islet amyloid polypeptide. PNAS 93 3492-3496
91. Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, SoeborgH&Knudsen LB 2012 The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. American Journal of Physiology. Endocrinology and Metabolism 303 E253-E264
92. Wang Q & Brubaker PL 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 1263-1273
93. Wang X, Cahill CM, Pineyro MA, Zhou J, Doyle ME & Egan JM 1999 Glucagon-like peptide-1 regulates the b cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140 4904-4907
94. Wang Q, Li L, Xu E, Wong V, Rhodes C & Brubaker PL 2004 Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 b cells. Diabetologia 47 478-487
95. Xu G, Stoffers DA, Habener JF & Bonner-Weir S 1999 Exendin-4 stimulates both β-cells replication and neogenesis, resulting in increased β-cells mass and improved glucose tolerance in diabetic rats. Diabetes 48 2270-2276
96. Yeom JA, Kim ES, Park HS, Ham DS, Sun C, Kim JW, Cho JH & Yoon KH 2011 Both sitagliptin analogue & pioglitazone preserve the β-cells proportion in the islets with different mechanism in non-obese and obese diabetic mice. BMB Reports 44 713-718
97. Zhang X, Wang Z, Huang Y & Wang J 2011 Effects of chronic administration of alogliptin on the development of diabetes and β-cells function in high fat diet/streptozotocin diabetic mice. Diabetes, Obesity & Metabolism 13 337-347